Genmab reported a 25% revenue increase to $896 million in Q1 2026, fueled by higher royalties from DARZALEX and Kesimpta, and increased sales of EPKINLY. The company advanced its late-stage drug portfolio, including EPKINLY, Rina-S, and petosemtamab, while maintaining disciplined investment and preparing for upcoming product launches. Operating profit was $180 million, slightly down from last year, but adjusted profit excluding acquisition costs rose. Genmab confirmed its 2026 financial guidance and continues to focus on expanding its pipeline and commercialization efforts.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Meta Platforms has been upgraded to a buy rating due to its new cloud business, which is expected to stabilize cash flow and improve profitability. Despite heavy capital expenditures, Meta maintains strong free cash flow margins and operational effic...
Willow Tree Research initiates coverage of Alnylam Pharmaceuticals with a non-consensus BUY rating, viewing the recent stock price decline as an overreaction. The company’s drug AMVUTTRA holds a near-term commercial monopoly in TTR silencing, with st...
SpaceX shares fell below their IPO price of $135 for the first time, dropping to $132.28 before closing slightly above at $135.27. The stock is down about 16% from its June 12 closing price and 36% from its peak on June 16. The decline reflects inves...
